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Abstract. Colon tumours are intrinsically resistant o che- 
motherapy and most of them express the multidrug transport- 
er P glycoprotein (Pgp). Whether this Pgp expression deter- 
mines their resistance to anticancer agents in patients is not 
known. We report here on the reversibility of intrinsic multi- 
drug resistance in a syngeneic, solid turnout model. CC531 is 
a rat colon carcinoma that expresses Pgp, as was shown with 
the monoclonal antibody C-219. In vitro the sensitivity to do- 
xorubicin, daunorubicin and colchicine was enhanced by the 
addition of the chemosensitizers verapamil and cyclosporin 
A (CsA), while the sensitivity to cisplatin was not enhanced. 
In a daunorubicin accumulation assay verapamil and CsA 
enhanced the daunorubicin content of CC531 cells. In vivo 
CsA was injected intramuscularly for 3 consecutive days at a 
dose of 20 mg kg -1 day -1. This resulted in whole-blood CsA 
levels above 2gmol/1, while intratumoral CsA levels 
amounted to 3.6 gmol/kg. In a subrenal capsule assay the 
maximal tolerable dose of doxorubicin (4 mg/kg) signifi- 
cantly reduced tumour growth. Doxorubicin at 3 mg/kg was 
not effective, but in combination with CsA this dose was as 
effective as 4 mg/kg doxorubicin. These experiments show 
that adequate doses of the chemosensitizing drug CsA can be 
obtained in vivo, resulting in increased antitumoral activity 
of doxorubicin in vivo. The in vitro and in vivo data together 
suggest hat the chemosensitization by CsA is mediated by 
Pgp. This finding may have implications for the application 
of CsA and CsA-like chemosensitizers in the clinical setting. 
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Introduction 
The phenomenon of multidrug resistance (MDR) to antican- 
cer agents can be an intrinsic characteristic of turnouts, or 
can be acquired by tumours during the course of chemother- 
apy. Among the tumours that intrinsically have a very low re- 
sponse rate to chemotherapy are colon cancer, renal cell can- 
cer, hepatocellular cancer and adrenocortical cancer. These 
turnouts have high expression levels of the gene for multi- 
drug resistance, mdr 1, at a high frequency (Goldstein et al. 
1989). The tissues from which they arise also have a high 
level of mdr 1 expression (Fojo et al. 1987). In these tissues 
the gene product of mdr 1, P glycoprotein (Pgp), may func- 
tion as an efflux pump for xenobiotics. It is striking that or- 
gans with the highest expression of mdr I all have excretory 
functions and that within these organs Pgp is principally 
found in cells lining excretory lumina (Thiebaut et al. 1987). 
Whether mdr expression in intrinsic MDR tumours is the 
most important factor determining their resistance to chemo- 
therapy, and whether blocking of Pgp or suppression of mdr 
expression can result in enhancement of cytotoxicity of anti- 
cancer drugs in the clinical situation, are still under study. 
Several drugs have been reported to reverse MDR in vi- 
tro. One of the most effective resistance-modifying agents is 
the immunosuppressive drug cyclosporin A (CsA) (Ford and 
Hait 1990). Many in vitro studies have shown an increase in 
cytotoxity to MDR cell lines when CsA is added to drugs that 
are affected by the MDR cross-resistance pattern, like do- 
xorubicin, vincristine and colchicine (Boesch et al. 1991 b; 
Gav6riaux et al. 1989; Twentyman et al. 1990). CsA, like 
other resistance-modifying agents, acts as a chemosensitizer 
almost only against MDR cell lines; the cytotoxicity to pa- 
rental cell lines that do not express Pgp is not influenced. On 
some cell lines CsA alone has antiproliferative and/or cyto- 
toxic effects, especially at higher doses of CsA (Twentyman 
et al. 1992). 
Compared to the abundance of in vitro data on the role of 
Pgp and the reversal of MDR by chemosensitizers, very few 
data on their value in vivo have been published, especially 
concerning their role in solid tumours. Most in vivo studies 
have been carried out with ascites tumours. In these models 
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intraper i toneal ly f loat ing tumour  cells are treated with intra- 
per i toneal  in ject ions of  drugs. In sol id tumours a prerequis i te 
is achieving effect ive drug concentrat ions at the turnout site 
by a vascular  oute. 
We invest igated the quest ion of  intr insic MDR in a synge- 
neic, sol id tumour  model.  We report  here on the chemosens i -  
t iz ing effects of  CsA  in vitro and in v ivo on an intr insic MDR 
rat co lon carc inoma. 
Materials and methods 
Animals. Male rats of the inbred WAG/RIJ (RT1 Ix) strain were obtained 
from Harlan-CPB (Austerlitz, The Netherlands). Animals were bred un- 
der specific-pathogen-free conditions and fed standard rat chow (Hope 
Farms, Woerden, The Netherlands) and water ad libitum. In the experi- 
ments rats 12-18 weeks old, weighing 220-280 g, were used. 
Tumours. CC531 is a colon carcinoma, which was induced chemically 
in the WAG rat with 1,2-dimethylhydrazine. Thetumour, a moderately 
differentiated a enocarcinoma, is weakly immunogenic and transplant- 
able in syngeneic rats (Marquet et al. 1984). In vitro the cell line grows 
as a monolayer in Dulbecco's modified Eagle's medium supplemented 
with 5% fetal calf serum, aspartic acid (0.1 raM), and glutamic acid 
(0.3 mM), all obtained from Gibco (Paisley, UK), in a humidified atmo- 
sphere of 5% CO2/95% air at 37 ~ C. Regular screening for Mycoplasma 
infection was performed. Cells were isolated by trypsinization; viability, 
determined by trypan blue exclusion, was over 90% in all experiments. 
The human ovarian carcinoma cell lines A2780 and 2780 AD (Rogan 
et al. 1984) were grown in complete medium. 2780 AD, a multidrug-resis- 
tant cell line with a high level of Pgp expression, was grown in the pres- 
ence of 1 gag doxorubicin. This cell line was used as a positive control 
in immunofluorescence studies, while the parental line, A2780, was 
used as a negative control. 
Chemicals. Cyclosporin A was obtained from Sandoz, Basel, Switser- 
land; doxorubicin (Adriablastina) from Farmitalia, Nivelles, Belgium; 
daunorubicin, colchicine, cis-diaminedichloroplatinum (cisplatin), ve- 
rapamil and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo- 
lium-bromide] from Sigma Chemical, St. Louis, MO; and dimeth- 
ylsulphoxide from Merck, Darmstadt, Germany. 
In vitro cytotoxicity assay. We determined chemosensitivity n vitro by 
the MTT assay, essentially carried out as described by Carmichael et al. 
(1987). In brief, in 48-well culture plates (Costar, Cambridge, Mass.) 
1500 cells were plated in 500 gl complete medium. Drugs were dis- 
solved in 0.9% NaC1. To each well 250 gl drug solution was added, us- 
ing a fixed concentration f the chemosensitizer and graded concentra- 
tions of the drugs. Cells were grown at 37 ~ C in 5% CO 2 humidified air. 
After 4 days 150 txl MTT, dissolved in PBS (phosphate-buffered saline) 
at a concentration f 2 mg/ml was added to each well. After an incuba- 
tion period of 4 h the supernatant was carefully removed and 250 IXl 
dimethylsulphoxide was pipetted to each well. Plates were placed in a 
microplate shaker for 5 rain. The content was pipetted into 96-well 
plates in order to read the absorbance at570 nm in an automatic microti- 
ter reader (EAR-400). Survival was calculated using the formula: sur- 
vival = (test well/control) x100%. The drug concentration reducing the 
absorbance to 50% of control (ICs0) was determined from the graphs. 
Sensitization ratios were determined by dividing the ICs0 in the absence 
of the resistance-modifying agent by the ICso in the presence of the 
chemosensitizer. 
Drug accumulation. In order to determine the accumulation ofdaunoru- 
bicin, cells were incubated with 1 Ixg/ml daunorubicin for 1 h at 37 ~ C. 
The content of the fluorescent drug in individual cells was measured on 
the FACStar Plus flow cytometer (Becton Dickinson, Mountain View, 
Calif.), equipped with a 4-W argon-ion laser tuned to 488 nm with 
300 mW power. Orange fluorescence pulses were collected through a 
575/26-nm bandpass filter. Results were calculated using the FACStar 
Plus research software (Gheuens et al. 1991). Enhancement of daunoru- 
bicin accumulation was tested by adding CsA (5 txM) and/or verapamil 
(6.6 IXM) to the incubation medium. Results are presented as mean fluo- 
rescence intensity. 
Immunofluorescence. Pgp expression was determined with the specific 
anti-Pgp monoclonal ntibody C-219, which recognizes an internal epi- 
tope of Pgp (Kartner et al. 1985). Single-cell suspensions of A2780, 
2780 AD, and CC531 were fixed with methanol 70% for 10min at 
-20 ~ C. Cells were washed three times in PBS and resuspended in PBS 
with 1% bovine serum albumin (Centocor, Leiden, The Netherlands). 
Next, cells were incubated with the monoclonal antibody C-219-FITC 
(fluorescein isothiocyanate conjugate; P-glyco-CHEK, Centocor) dilut- 
ed 1:100, for 60 min on ice. IgG2a-FITC was used as a control antibody, 
to determine the aspecific and/or autofluorescence of the cells. After 
three washings in PBS, cells were analysed on the FACStar Plus flow 
cytometer using green fluorescence pulses, collected through a 530/30- 
nm bandpass filter. 
In vivo assay. Solid tumours of the CC531 cell line were obtained by in- 
traperitoneal inoculation of 5x106 tumour cells. After 30-40 days a rat 
carrying a large tumour mass was sacrificed and a viable tumour part 
was excised and divided into small pieces. In a subrenal capsule assay 
(SRCA) tumour pieces weighing 6 8 mg were implanted under the cap: 
sule of the kidneys. Rats were matched for implanted tumour weight in 
the different reatment groups. On the same day CsA treatment was 
started. CsA, dissolved in olive oil, was injected intramuscularly into the 
hind leg daily, for 3 consecutive days at a dose of 20 mg/kg, in order to 
generate sustained high levels of CsA. On day 3, rats were injected with 
3 mg/kg or 4 mg/kg doxorubicin, or PBS in control rats. After 10 days 
animals were sacrificed and tumours were enucleated and weighed. All 
experimental groups consisted of six rats and all animals were evaluable. 
Cyclosporin A levels. CsA levels in vivo were determined with the Emit 
cyclosporin assay (Syva, Palo Alto, Calif.) on the ELAN analyser (Ep- 
pendorf, Hamburg, Germany). This homogeneous enzyme immunoas- 
say is designed for measuring CsA levels in whole blood. Blood samples 
were taken 24 h after the third injection of CsA. Whole blood samples 
(100 IXl) were mixed with 200 gl 100% methanol, which solubilizes 
CsA. The samples were centrifuged and aliquots of the supernatant con- 
taining the CsA were diluted with Emit cyclosporin diluent before as- 
saying. In order to measure intratumoral CsA levels, turnouts were 
grown under the renal capsule for 10 days. On day 7, 8 and 9 CsA 
(20 mg/kg) was administered intramuscularly. On day 10 rats were sac- 
rificed and tumours were enucleated without renal tissue. Tumours were 
crushed in a small tube in 300 gl methanol with a pestle for 3 rain. Then 
200 IXl solution was mixed with 100 Ixl normal rat whole blood and as- 
sayed as a blood sample. The results were corrected for dilution steps 
and calculated per kilogram tumour tissue, while the plasma nd whole 
blood levels are presented per liter. As the weight of 1 1 whole blood is 
1.06 kg, the results of the tissue levels and the blood levels are compar- 
able. Because the CsA levels appeared to be very high, an additional di- 
lution step was necessary to reach the measurable range of the assay. 
Blood samples and turnout samples were taken from three rats and rep- 
resented individually in the graph. 
Statistics. Statistical significance was determined with SPSS/PC+, using 
the Mann-Whitney U/Wilcoxon rank-sum Wtest. P<0.05 was consid- 
ered significant. Results are presented as means with standard evia- 
tions. 
Ethical approval. The experimental protocols adhered to the rules laid 
down in The Dutch Animal Experimentation Act (1977) and the Guide- 
lines on the Protection of Experimental Animals published by the Coun- 
cil of the E.C. (1986). Specific protocols were approved by the Commit- 
tee on Animal Research of the Erasmus University, Rotterdam. 
Results 
In vitro chemosensitizing effect 
In the first tests we used the best -known chemosensit izer ,  ve- 
rapamil .  At  a concentrat ion of  6.6 IxM growth inhib i t ion of 
Table 1. Chemosensitizing effect of verapamil (VPL) on growth inhibi- 
tion by drugs in CC531 cells 
Drug ICs0 -VPL ~ ICs0 +VPL a Sensitization ratio b 
Colchicine 0.081 (_+0.021) 0.028 (_+0.001) 2.9 
Daunorubicin 0.200 (_+0.113) 0.030 (_+0.002) 6.7 
Cisplatin 0.600 (_+0.120) 0.865 (_+0.087) 0.7 
a The drug concentration that results in a 50% reduction of the absorb- 
ance in the MTT assay; the values in parentheses are standard eviations 
The mean sensitization ratio is shown. All experiments were carried 
out at least hree times 
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Fig. 1. Dose/response curves of the ceil line CC531 to doxorubicin 
(DOX) in the absence or presence of various concentrations of cyclospo- 
rin A (CsA) determined inthe MTT assay. Cell number, measured as ab- 
sorbance in the colorimetric assay, is represented asa percentage of the 
control cell growth on the y axis 
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Table 2. Effect of chemosensitizers on daunorubicin (DNR) accumula- 
tion 
Drugs DNR content" 
DNR 100 
DNR+CsA 211_+38 
DNR+VPL 193_+20 
Numbers represent the mean fluorescence intensity of daunorubicin 
CC531 cells after incubation with and without chemosensitizers. Dau- 
norubicin: 1 Ixg/ml; cyclosporin A (CsA) 5 txM; verapamil (VPL) 
6.6 p~M. The fluorescence ofdaunorubicin alone is arbitrarily defined as 
100. The experiments were repeated at least wice 
the cell l ine CC531 by drugs like daunorubicin and col- 
chicine was enhanced. Verapamil was not able to ampli fy the 
growth-inhibit ing effect of  cisplatin. In contrast, some 
growth enhancement was observed (Table 1). At lower con- 
centrations the eff icacy of  verapamil  diminished rapidly: at a 
concentration of  1 txM only a small chemosensit iz ing effect 
was seen. Next we tested the chemosensit iz ing potential of  
CsA; in Fig. 1 a representative experiment is shown. CsA had 
a concentrat ion-dependent chemosensit iz ing effect on 
growth inhibition by doxorubicin and was active at concen- 
trations as low as 0.1 o~M. The mean sensitization ratio of  0.5 
IxM CsA to doxorubicin cytotoxicity was 6.6. 
Enhancement of drug accumulation 
Table 2 shows the results of  the daunorubicin accumulat ion 
study. The mean f luorescence intensity, a measure for the in- 
tracellular daunorubicin quantity, calculated from the histo- 
r  e~ 
(K 
O0 A ' -  
Fig. 2. P glycoprotein expression i A2780, 2780 AD and 
CC531 cells determined by flow cytometry with the mono- 
clonal antibody C-219. The figure shows cell count on the 
x axis (linear scale) and fluorescence intensity (fluorescein- 
isothiocyanate-labelled C-219) on the y axis (logarithmic 
scale) 
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Fig. 3. Cyclosporin A (CsA) levels in plasma, whole blood and in CC531 
tumours determined with the Emit cyclosporin assay. The results of 
three animals are represented individually. The units used for CsA levels 
in plasma nd whole blood are ixmol/l, in tumour tissue ixmol/kg 
grams, increased under the influence of 5 txM CsA 2.1 times. 
At this concentration CsA was as effective as 6.6 ixM verapa- 
mil. 
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Fig. 4. Effect of doxombicin (DOX) and/or the chemosensitizer cyclos- 
porin A (CsA) on weights of CC531 tumours in the subrenal capsule as- 
say experiment. Contr, control, no drug treatment; CsA-contr, only treat- 
ment with CsA; DOX3, rats treated with 3 mg/kg doxorubicin; 
DOX3+CsA, rats treated with 3 mg/kg doxorubicin, and CsA; DOX4, 
rats treated with 4 mg/kg doxombicin, DOX4 + CsA, rats treated with 4 
mg/kg doxorubicin, and CsA. The following groups were significantly 
smaller compared to other groups (determined with the Mann-Whitney 
UfvVilcoxon rank-sum W test): (a) DOX3+CsA versus Contr 
(P=0.0039), CsA-contr (P=0.0039), and DOX3 (P=0.0163); (b) DOX4 
versus Contr (P=0.0039), and CsA-contr (P=0.0039); (c) DOX4+CsA 
versus Contr (P=0.0039), CsA-contr (P=0.0039), DOX3 (P=0.02), and 
DOX4 (P=0.0039) 
Ideally immunofluoresence studies should be carried out 
with a monoclonal antibody that recognizes an external epi- 
tope of a membrane protein. Using an antibody that recog- 
nizes an internal epitope requires membrane disturbance by 
fixation with the drawback of possible loss of intensity be- 
cause of epitope loss by this fixation. However, for rat Pgp 
there is no monoclonal antibody available that recognizes an 
external epitope, as MRK-16 is humanspecific and the anti- 
bodies HYB-241 and 265/F4 do not recognize rat Pgp (un- 
published observations). Therefore we tested with C-219, an 
antibody widely used to determine Pgp expression. In Fig. 2 
a distinct difference is seen between the non-Pgp-expressing 
A2780, and the Pgp-expressing 2780 AD. The fluorescence 
peak of CC531 cells bound to C-219-FITC lies between that 
of the two control cell lines, just to the right of A2780, dem- 
onstrating the Pgp expression in CC531 cell. 
In vivo cyclosporin A levels 
Because we had no data on the bio-availibility of CsA in tu- 
mours, we chose to administer CsA at a higher dose than nec- 
essary to reach a chemosensitizing effect on CC531 cells in 
vitro. With the injection of 20 mg kg -I day < on 3 consecutive 
days, an intramuscular depot was generated, which gave sus- 
tained high levels of CsA. Whole blood levels, determined 
24 h after the last injection of CsA (about 2 h before the ad- 
ministration of doxorubicin), amounted to 2.1 (+ 0.2) Nnol/1. 
In a separate xeriment blood and intratumoral CsA levels 
were compared. The CsA level in whole blood was again 
2.1 p, mol/1. Intratumoral CsA levels, measured with the 
same method, amounted to 3.6 ~amol/kg, which is higher than 
in whole blood. See Fig. 3. 
In vivo chemosensitizing effect 
In the SRCA doxorubicin alone, administered atthe maximal 
tolerable dose of 4 mg/kg, significantly inhibited tumour 
growth (Fig. 4). A lower dose of 3 mg/kg had no significant 
growth-retarding effect. In combination with CsA both doses 
of doxorubicin were significantly more effective compared 
to treatment with the respective doses of doxornbicin alone. 
Treatment with CsA alone had no effect on tumour growth. A 
repeat experiment with 4 mg/kg doxorubicin showed a sig- 
nificant chemosensitizing effect of CsA also at the 4 mg/kg 
dose level. 
Discussion 
In this study we show the feasibility of overcoming intrinsic 
MDR in a rat colon adenocarcinoma in vivo. We believe that 
the CC531 tumour provides a good, syngeneic, solid tumour 
model for studying intrinsic MDR. In vivo CC531 is very re- 
sistant o most anticancer drugs and only a moderate sensitiv- 
ity to cisplatin has been described (Los et al. 1990). In our ex- 
periments a significant growth-retarding effect could be 
obtained by using doxorubicin, but only when used at the 
maximal tolerable dose of 4 mg/kg, while no significant gro- 
wth inhibition was observed at lower dosage. In in vitro cyto- 
toxicity tests the addition of chemosensitizers enhanced the 
growth-inhibiting effect of daunorubicin, doxorubicin and 
colchicine, drugs of the cross-resistance pattern of MDR, 
whereas the cytotoxicity of cisplatin was not enhanced by 
CsA. We demonstrated by flow cytometry that co-incubation 
of daunorubicin with chemosensitizers like CsA and verapa- 
mil results in an enhanced accumulation of daunorubicin in 
613 
cells. A distinct expression of Pgp was shown by immunoflu- 
orescence. These data indicate that CC531 has the typical 
MDR phenotype. 
Of the drugs that are able to reverse MDR in vitro, verapa- 
mil is the best known and most intensely studied. However, 
levels of verapamil necessary to reverse MDR in vitro, about 
5 IxM, can not be reached in patients because of prohibitive 
cardiovascular toxicity (Pennock et al. 1991). We chose CsA 
as a chemosensitizer because several investigators eported a
higher effectivity on an equimolar basis of CsA over verapa- 
rail (Boesch et al. 1991b; Silberman et al. 1989; Twentyman 
et al. 1990), a result we also found with the CC531 cell line. 
The second reason we chose CsA was that the concentration 
of CsA necessary in vitro to overcome drug resistance is 
achievable without intolerable side-effects in vivo in humans 
(Verweij et al. 1991; Sonneveld et al. 1992). However, one 
can not translate in vitro concentrations directly into doses re- 
quired in vivo, as pharmacological aspects may play an im- 
portant role in the bio-availability of the drug (Kaye 1990), 
e.g. in vivo over 95% of CsA is bound to proteins or cells. 
Therefore we decided to administer CsA at a higher dose than 
required to achieve a chemosensitizing effect in our in vitro 
experiments. After 3 days of intramuscular administration, 
CsA levels in whole blood obtained in the in vivo experiments 
were above 2 ixmol/1. Interestingly, measured with the same 
cyclosporin assay, intratumoral levels of CsA amounted to 3.6 
ixmol/kg, which suggests that in solid tumours CsA levels 
may be even higher than in whole blood. This means that ad- 
equate levels of the chemosensitizer CsA can be reached at 
the tumour site by a vascular route. In vivo this dose had nei- 
ther a growth-retarding, nor a growth-stimulating effect on 
the tumour: in the SRCA, tumours in the control group or tu- 
mours treated with CsA alone had similar weights. 
In this intrinsic MDR model we show that CsA can have 
an effective chemosensitizing effect on doxorubicin in vivo. 
In the SRCA experiment rats treated with the combination of 
CsA and doxorubicin had significantly smaller tumours 
compared to all other groups and also compared to the rats 
treated with doxorubicin alone. Adding CsA to doxorubicin 
rendered a suboptimal dose of 3 mg/kg doxorubicin effec- 
tive, and the activity of an effective dose of 4 mg/kg was en- 
hanced by combination with CsA. The differences in stan- 
dard errors between the experimental groups, with larger 
errors in the control groups and less variation in results in the 
treated groups, is a phenomenon that is often seen in experi- 
mental pharmacology. Probably this is due to the logarithmic 
growth of tumours, which is attenuated for some time in ef- 
fectively treated groups, resulting in smaller tumours with in- 
herently smaller standard errors. 
Together with the in vitro data, demonstrating Pgp ex- 
pression, enhancement of drug uptake and increased growth 
inhibition in CC531 cells by the addition of CsA, these find- 
ings furnish evidence for direct MDR reversal at the cellular 
tumour level. However, an alternative xplanation, CsA al- 
tering drug pharmacokinetics (Sikic et al. 1992), can not be 
ruled out. As Pgp expression is found in the kidneys, espe- 
cially in the renal tubules (Thiebaut et al. 1987), blocking of 
this efflux pump may diminish excretion of anticancer drugs 
and, via higher and more prolonged blood levels, cause indi- 
rect enhanced exposure of cells to drugs (Sikic et al. 1992). 
In vivo reversibility of drug resistance by CsA has been 
reported in other, mostly non-solid tumour models. In ascites 
tumour models, Slater et al. (1986) found a correction of dan- 
norubicin resistance by CsA on a daunorubicin-resistant sub- 
line of the Ehrlich ascites tumour in vivo, and they also de- 
scribed enhancement of the cytotoxicity of daunorubicin by 
CsA to the parental Ehrlich ascites and hepatoma 129 
(Meador et al. 1987). Boesch et al. (1991a), however, did not 
find any effect of CsA on vincristine cytotoxicity to an MDR 
variant of the murine monocytic leukemia P388. Only 
Osieka et al. (1986) published a study about a solid tumour 
and showed enhancement of etoposide cytotoxicity by CsA 
to a human embryonal carcinoma in nude mice. We feel that 
our tumour model is, therefore, a valuable one, as it is both a 
syngeneic, and a solid, MDR-positive tumour. 
Although our experiments suggest potential use for CsA 
in the clinical setting, results in the few trials reported so far 
have not yet substantiated itsrole, as they are not unequivo- 
cal. Sonneveld and Nooter (1990) showed the possibility of 
eliminating mdrl-positive acute myeloid leukemia cells by 
adding CsA to an ineffective treatment schedule. In a very re- 
cent report hey described reversal of clinical drug resistance 
in patients with multiple myeloma fter addition of CsA to 
the combination chemotherapy (Sonneveld et al. 1992). Re- 
sponse was correlated with Pgp and mdrl expression. Stea- 
dy-state plasma levels of CsA were about 1000 btg/1. Verweij 
et al. (1991) tested CsA as a resistance-modifying agent in 
combination with epidoxorubicin in colorectal cancer. In 
four out of four tumour samples they showed the ability of 
CsA to enhance daunorubicin uptake by flow cytometry. De- 
spite this observation, only 1 patient out of 24 had a partial 
response, while 2 of the patients who showed enhanced au- 
norubicin uptake in vitro had progressive disease. The CsA 
levels they reported seem quite high and adequate: peak lev- 
els of about 6000 ng/ml and levels around 1000 ng/ml 18 h 
later. Similar CsA levels were achieved in a clinical trial in 
renal cell cancer patients with the combination CsA plus 
vinblastine. No response was found in 15 patients (Rodenburg 
et al. 1991). Although mdr levels or Pgp expression were not 
determined in these studies, it is likely that a substantial num- 
ber of these 39 patients expressed Pgp in their tumours, as in 
other studies colon carcinoma s well as renal cell cancer 
was found to be mdr- or Pgp-positive in the majority of the 
patients (Mizoguchi et al. 1990; Weinstein et al. 1991; Kana- 
maru et al. 1989; Mickisch et al. 1990; Van Kalken et al. 
1991). Moreover, Kanamaru et al. (1989) and Mickisch et al. 
(1990) showed that Pgp expression in renal cell carcinomas 
correlated with resistance in primary cell cultures in vitro to 
doxorubicin and vinblastine, which could be reversed by 
chemosensitizers. The clinical trials by Rodenburg et al. 
(1991) and Verweij et al. (1991) are the only studies that 
dealt exclusively with tumours from organs that inherently 
have a high expression level of Pgp. Other studies were car- 
ried out in heavily pretreated patients or patients with ad- 
vanced disease. In these studies, a clear response was found 
in a trial with patients with myeloma or lymphoma resistant 
to vincristine/doxorubicirddexamethasone: 3 out of 8 pa- 
tients responded to the addition of verapamil to the drug reg- 
imen, while 6 of these 8 patients exhibited Pgp expression on 
their tumour cells (Dalton et al. 1989). So this last study and 
614 
the study by Sonneveld et al. (1992) clearly suggest a bene- 
fical role of resistance-modifying agents. 
So far only clinical trials with haematological disorders 
have been succesful in reversing MDR. In solid tumours no 
responses were found. We cannot compare our experimental 
data with clinical trials, but we show in our model the feasi- 
bility of reversing intrinsic MDR in a solid tumour in vivo. 
Adequate levels of the chemosensitizer CsA could be ob- 
tained at the tumour site 'by a vascular oute, and this ren- 
dered a suboptimal dose of doxorubicin effective. Our re- 
sults, obtained in a syngeneic, solid tumour model therefore 
suggest that there may still be a place for chemosensitizers in 
the chemotherapy of MDR solid tumours. 
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